Table 1.
Antiviral activity against HIV replication in MT-4 cells.
| |||||||
|---|---|---|---|---|---|---|---|
| Compounds | R | EC50a(μM) |
CC50c (μM) | SId |
|||
| IIIB | ROD | ratiob | IIIB | ROD | |||
| 7a | Ph | 22.37 ± 9.81 | 2.40 ± 0.26 | 9.32 | >234.01 | >10.46 | >97.50 |
| 7b | 4-F-Ph | 31.80 ± 6.34 | 3.66 ± 2.99 | 8.69 | 54.01 ± 2.48 | 1.70 | 14.76 |
| 7c | 4-Br-Ph | ≥185.61 | 6.21 ± 0.95 | >29.89 | >204.22 | N.D.e | >32.89 |
| 7d | 4-Cl-Ph | >220.02 | 3.85 ± 1.00 | >57.15 | >220.02 | N.D.e | >57.15 |
| 7e | 3-F-Ph | >226.38 | 2.84 ± 0.20 | >79.71 | >226.39 | N.D.e | >79.71 |
| 7f | 2-F-Ph | 21.88 ± 5.89 | 2.01 ± 0.18 | 10.88 | 66.38 ± 13.31 | 3.03 | 33.02 |
| 7g | 4-CH3-Ph | 41.15 ± 8.83 | 3.30 ± 1.64 | 12.47 | >228.02 | >5.54 | >69.10 |
| 7h | 4-CH3O-Ph | ≥204.92 | 3.72 ± 1.17 | 55.09 | >221.56 | ≤1.08 | >59.56 |
| 7i | 4-F3C-Ph | ≥39.49 | >88.22 | N.D.e | 88.22 ± 73.35 | ≤2.23 | <1 |
| 7j | 4-CH3CO-Ph | >164.95 | 19.18 ± 7.19 | 8.60 | 164.95 ± 26.33 | <1 | 8.60 |
| 7k | 4-F3CO-Ph | 34.89 ± 1.23 | ≥31.08 | ≤1.12 | 118.13 ± 56.20 | 3.39 | ≤3.80 |
| 7l | 4-CN-Ph | 13.20 ± 2.52 | 6.83 ± 1.23 | 1.93 | >223.55 | >16.94 | >32.73 |
| 7m | Propargyl | 5.02 ± 2.02 | 0.85 ± 0.48 | 5.91 | 133.61 ± 9.71 | 26.62 | 157.19 |
| 7n | Methoxyethyl | 15.69 ± 0.50 | 2.42 ± 0.60 | 6.48 | 203.38 ± 27.68 | 12.96 | 84.04 |
| 7o | 4-pyridyl | ≥41.41 | 3.51 ± 0.67 | 11.80 | 37.63 ± 7.19 | <0.91 | 10.72 |
| 7p | N-Boc-piperazine | 13.50 ± 0.29 | 2.68 ± 0.49 | 5.04 | 93.90 ± 19.78 | 6.96 | 35.04 |
| 7q | N-Boc-piperidine | >29.32 | 2.78 ± 0.19 | 10.55 | 29.32 ± 2.88 | <1 | 10.55 |
| 7r | 4-(N-BoceNH2)–Ph | >2.23 | >2.23 | N.D.e | 2.23 ± 1.11 | <1 | <1 |
| 7s | 3-(N-BoceNH2)–Ph | >192.53 | 28.28 ± 19.78 | 6.81 | >192.53 | N.D.e | >6.81 |
| 7t | 2-(N-BoceNH2)–Ph | 138.96 ± 25.43 | 2.46 ± 0.11 | 56.49 | >192.53 | >1.39 | >78.26 |
| 7u | 4-NH2-Ph | 3.57 ± 0.27 | 2.93 ± 0.33 | 1.22 | 57.36 ± 17.88 | 16.07 | 19.58 |
| 7v | 3-NH2-Ph | 23.71 ± 10.83 | 1.55 ± 0.58 | 15.30 | 133.60 ± 59.03 | 5.63 | 86.19 |
| 7w | 2-NH2-Ph | >25.37 | 1.84 ± 0.35 | 13.79 | 25.37 ± 0.76 | <1 | 13.79 |
| PF74 | 0.75 ± 0.33 | 4.16 ± 2.02 | 0.18 | 32.27 ± 2.94 | 43.03 | 7.76 | |
a
EC50: concentration of compound required to achieve 50% protection of MT-4 cell cultures against HIV-1-induced cytotoxicity, as determined by the MTT method.
b
EC50(IIIB)/EC50(ROD) ratio.
c
CC50: concentration required to reduce the viability of mock-infected cell cultures by 50%, as determined by the MTT method.
d
SI: selectivity index, the ratio of CC50/EC50.
e
N.D.: not determined.